Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
Clinical Assessment and Indication
- The American Academy of Ophthalmology indicates that patients with confirmed chronic central serous chorioretinopathy (CCSC) in one eye with symptoms persisting for over one year meet the duration criterion for PDT treatment, which requires a duration of 3 months or longer 1, 2
- Fluorescein angiography is an essential diagnostic criterion for PDT authorization, confirming the diagnosis of CCSC 1
- OCT imaging shows worsening and persistent subretinal fluid with significant retinal thickness, indicating active disease requiring intervention 1, 3
- Patients with CCSC report persistent visual disturbances, indicating significant impact on quality of life 4
Evidence Supporting PDT for CCSC
- Current evidence-based guidelines recommend half-dose or half-fluence PDT with verteporfin as the preferred treatment for chronic CSC, targeting the abnormal choroid 1, 2
- PDT targets the primary pathophysiological mechanism in CSC, the abnormal choroid, leading to complete resolution of subretinal fluid in 83-100% of CCSC cases 1, 3, 5
- Clinical studies demonstrate that PDT provides faster subretinal fluid resolution, more rapid recovery of retinal sensitivity, and higher best-corrected visual acuity compared to observation alone 2, 6
Treatment Protocol Considerations
- Half-dose (3 mg/m²) or half-fluence PDT is recommended over full-dose PDT to minimize potential side effects while maintaining efficacy 1, 5
- Post-treatment precautions include avoiding direct sunlight and other sources of UV radiation for 48-72 hours after receiving PDT 5
- Patients should wear protective clothing and stay out of the sun for 72 hours following the laser procedure, as advised in the treatment plan 7
Expected Outcomes
- Follow-up imaging at 4-6 weeks post-treatment is appropriate to assess treatment response 7
- The risk of recurrence after successful PDT treatment is significantly lower than with observation alone 2